FORMULATION AND EVALUATION OF NOVEL NASAL DELIVERY SYSTEM FOR THE TREATMENT OF RHINITIS

2016-10-16T02-20-53Z
Source: Indo American Journal of Pharmaceutical Research
Vaishali Potnis*, Manoj Kashid, Suchita Dhamne, Nitin Mogal.
The fast rate of urbanization, has considerably elevated the prevalence of upper respiratory tract diseases, especially that of allergic rhinitis (AR).More than 10-30 % of the population, world-wide, is found to be affected by AR. Conventional therapy of AR is dominated by oral dosage forms of H1 blocker anti-histaminic agents and nasal decongestants while the use of steroids is reserved only for severe and non-responsive cases. Frequent administration of these agents, the severity of their side effects, significantly contributes to poor compliance by the patients. In view of this, an in-situ gelling nasal system for combined and sustained delivery of Deslorantadine (DSL), a third generation antihistaminic and Phenylephrine hydrochloride, α1-adrenergic blocker has been designed. The mechanism employed for sustained release of APIS is based on in- situ transition of trigger sensitive polymeric solutions, into more viscous and muco-adhesive gel in the nasal passage. The sol and gel phases of the formulations were characterized for pH, viscosity, muco-adhesive strength, contents and diffusion profiles of APIs. The formulation CP4H1K1DP, based on pH sensitive carbomer, possessed superior gelling characteristics, physiologically acceptable pH range, muco-adhesive strength (5865 dynes/cm2) and prolonged diffusion (in-vitro) over 6 hrs. The key stability parameters of this formulation were unaffected during the storage over 30 days, suggesting its suitability as an alternative to the existing treatment options for AR.


from Scope via xlomafota13 on Inoreader http://ift.tt/2dFRqSC
via IFTTT